The Cape Town company that has signed with Pfizer and BioNTech to produce their Covid vaccine for distribution in Africa is planning a new €130m (about R2bn) facility that could produce up to 500-million doses a year by 2026, and is in talks with development finance institutions (DFIs) to fund this.

The Biovac Institute, which was SA's only vaccine manufacturer until Aspen entered the market with the Johnson & Johnson (J&J) Covid vaccine earlier this year, is to start producing the Pfizer-BioNTech vaccine by the end of this year, ramping up to 100-million doses a year in terms of its agreement with the two companies...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now